Laboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, Japan.
Laboratory for Mucosal Immunity, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, Japan.
Nat Commun. 2024 Nov 29;15(1):10129. doi: 10.1038/s41467-024-54308-9.
Despite its broad application in in vitro studies, the application of targeted protein degradation (TPD) to animal models faces considerable challenges. Here, we develop inducible and cell-type specific TPD systems in mice using two degron systems: Oryza sativa TIR1 (OsTIR1)-auxin-inducible degron 2 (AID2) and human cereblon (hCRBN)-SALL4 degron (S4D). Efficient degradation of Satb1 protein by these systems recapitulates phenotypes observed in the Satb1-deficient mice. These TPD are successfully applied in both the fetal and neonatal stages. The OsTIR1-AID2 system proves to be effective for membrane proteins such as PD-1, emulating the effects of the anti-PD-1 antibody. Degradation of Bcl11b reveals a role of Bcl11b which was not characterized by the Cre-loxP system. Collectively, in vivo TPD technologies developed in this study enable inducible, temporal, and cell type-specific depletion of target proteins with high efficacy in mice. These technologies have a wide range of applications in the diverse fields of biological and medical research.
尽管靶向蛋白降解(TPD)在体外研究中得到了广泛应用,但将其应用于动物模型仍面临相当大的挑战。在这里,我们使用两种 degron 系统——水稻 TIR1(OsTIR1)-生长素诱导的 degron 2(AID2)和人 cereblon(hCRBN)-SALL4 degron(S4D),在小鼠中开发了诱导型和细胞类型特异性的 TPD 系统。这些系统有效地降解了 Satb1 蛋白,重现了 Satb1 缺陷小鼠中观察到的表型。这些 TPD 在胎儿和新生儿阶段都成功应用。OsTIR1-AID2 系统对 PD-1 等膜蛋白也很有效,模拟了抗 PD-1 抗体的作用。Bcl11b 的降解揭示了 Bcl11b 的作用,这一作用不能用 Cre-loxP 系统来描述。总之,本研究中开发的体内 TPD 技术能够在小鼠中高效诱导、定时和细胞类型特异性地耗尽靶蛋白。这些技术在生物和医学研究的各个领域有广泛的应用。